Eli Lilly and Company (NYSE:LLY) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Eli Lilly and Company (NYSE:LLYGet Rating) have been assigned a consensus rating of “Moderate Buy” from the nineteen analysts that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $359.78.

LLY has been the subject of several research analyst reports. Argus raised their price target on Eli Lilly and from $315.00 to $360.00 in a research report on Friday, September 30th. StockNews.com initiated coverage on Eli Lilly and in a research report on Wednesday, October 12th. They set a “buy” rating for the company. UBS Group upgraded Eli Lilly and from a “neutral” rating to a “buy” rating and raised their price target for the stock from $335.00 to $363.00 in a research report on Thursday, September 22nd. Berenberg Bank raised their price target on Eli Lilly and from $345.00 to $375.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Citigroup raised their price target on Eli Lilly and from $285.00 to $370.00 in a research report on Thursday, August 25th.

Insider Buying and Selling at Eli Lilly and

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 149,264 shares of the firm’s stock in a transaction on Thursday, October 6th. The stock was sold at an average price of $334.54, for a total value of $49,934,778.56. Following the sale, the insider now directly owns 103,624,546 shares in the company, valued at $34,666,555,618.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, major shareholder Lilly Endowment Inc sold 149,264 shares of Eli Lilly and stock in a transaction dated Thursday, October 6th. The stock was sold at an average price of $334.54, for a total transaction of $49,934,778.56. Following the sale, the insider now owns 103,624,546 shares in the company, valued at $34,666,555,618.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Alonzo Weems sold 656 shares of Eli Lilly and stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $326.23, for a total value of $214,006.88. Following the sale, the executive vice president now owns 6,950 shares in the company, valued at approximately $2,267,298.50. The disclosure for this sale can be found here. Insiders have sold a total of 571,297 shares of company stock worth $193,929,777 over the last ninety days. Corporate insiders own 0.12% of the company’s stock.

Institutional Trading of Eli Lilly and

A number of hedge funds and other institutional investors have recently made changes to their positions in LLY. Cordant Inc. acquired a new stake in shares of Eli Lilly and during the first quarter worth about $25,000. Insight Inv LLC purchased a new position in shares of Eli Lilly and during the second quarter worth about $26,000. Castle Wealth Management LLC purchased a new position in shares of Eli Lilly and during the second quarter worth about $28,000. Horan Securities Inc. grew its holdings in shares of Eli Lilly and by 96.0% during the second quarter. Horan Securities Inc. now owns 98 shares of the company’s stock worth $32,000 after buying an additional 48 shares during the last quarter. Finally, Cypress Capital Management LLC WY grew its holdings in shares of Eli Lilly and by 300.0% during the second quarter. Cypress Capital Management LLC WY now owns 100 shares of the company’s stock worth $32,000 after buying an additional 75 shares during the last quarter. Institutional investors and hedge funds own 82.45% of the company’s stock.

Eli Lilly and Trading Down 0.1 %

Shares of Eli Lilly and stock opened at $360.88 on Friday. Eli Lilly and has a fifty-two week low of $231.87 and a fifty-two week high of $369.80. The stock has a 50 day moving average of $337.81 and a 200 day moving average of $320.94. The firm has a market capitalization of $342.90 billion, a price-to-earnings ratio of 54.19, a PEG ratio of 2.28 and a beta of 0.36. The company has a debt-to-equity ratio of 1.39, a quick ratio of 0.88 and a current ratio of 1.13.

Eli Lilly and Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Shareholders of record on Tuesday, November 15th will be paid a $0.98 dividend. This represents a $3.92 dividend on an annualized basis and a yield of 1.09%. The ex-dividend date is Monday, November 14th. Eli Lilly and’s dividend payout ratio is presently 58.86%.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Articles

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.